187
Views
6
CrossRef citations to date
0
Altmetric
Rapid Communication

Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study

, ORCID Icon, , , , , , , & ORCID Icon show all
Pages 5287-5291 | Published online: 10 Dec 2021

References

  • World Health Organization. WHO coronavirus (COVID-19) dashboard. Available from: https://covid19.who.int/. Accessed July 21, 2021.
  • Lamontagne F, Agoritsas T, Macdonald H, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379. doi:10.1136/bmj.m337932887691
  • Parker WB. Metabolism and antiviral activity of ribavirin. Virus Res. 2005;107(2):165–171. doi:10.1016/j.virusres.2004.11.00615649562
  • Burrows FS, Carlos LM, Benzimra M, et al. Oral ribavirin for respiratory syncytial virus infection after lung transplantation: efficacy and cost-efficiency. J Heart Lung Transplant. 2015;34(7):958–962. doi:10.1016/j.healun.2015.01.00925753833
  • McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med. 1986;314(1):20–26. doi:10.1056/NEJM1986010231401043940312
  • Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256. doi:10.1136/thorax.2003.01265814985565
  • Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19(10):1313–1317. doi:10.1038/nm.336224013700
  • Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARSCoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study.Life Sci. 2020;253:117592. doi:10.1016/j.lfs.2020.117592
  • Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-032020029
  • China NHCotPsRo. Chinese management guideline for COVID-19 (version 8.0); 2020. Available from: https://www.chinadaily.com.cn/pdf/2020/DiagnosisandTreatmentProtocolforCOVID-19Patients(Tentative8thEdition).pdf. Accessed August 18, 2020.
  • Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. doi:10.1056/NEJMoa200128232187464
  • Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. doi:10.1016/S0140-6736(20)31022-932423584
  • Wang Y, Zhang L, Sang L, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest. 2020;130(10):5235–5244. doi:10.1172/JCI13875932634129
  • Pujadas E, Chaudhry F, McBride R, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir Med. 2020;8(9):e70. doi:10.1016/S2213-2600(20)30354-432771081
  • Fajnzylber J, Regan J, Coxen K, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020;11(1):5493. doi:10.1038/s41467-020-19057-533127906
  • Hung IF, Lung K, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695–1704. doi:10.1016/S0140-6736(20)31042-432401715
  • Tong S, Su Y, Yu Y, et al. Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents. 2020;56(3):106114. doi:10.1016/j.ijantimicag.2020.10611432712334
  • Yin P, Meng J, Chen J, et al. Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study. Virol J. 2021;18(1):142. doi:10.1186/s12985-021-01617-w34238341